Tag Archives: study

Big time losers and the reasons why (BPAX, AIS, IPSU)

Posted on December 15, 2011 by Josie Middleton

In this report: BioSante Pharmaceuticals (NASDAQ:BPAX), Antares Pharma (AMEX:AIS) and Imperial Sugar (NASDAQ:IPSU).

BioSante Pharmaceuticals (NASDAQ:BPAX) tanked by more than 77 percent today after the company’s “Female Viagra” drug failed a late stage study which then led to several downgrades …

Posted in Latest Headlines, Reports | Tagged AIS, AMEX:AIS and Imperial Sugar, analysis, Analysts, Antares Pharma, BioSante Pharmaceuticals, BPAX, company, downgrades, drug, filed, investors, IPSU, JMP Securities, late stag, Leerink, LiBiGel, MLV & Co, NASDAQ:BPAX, NASDAQ:IPSU, Oppenheimer, patents, Phase 3, report, Rodman & Renshaw, Roth Capital, S, study, tanked, testosterone, trial | Comments Off

What the fuss Pacira, Amtech Systems and BioSante?

Posted on November 16, 2011 by Josie Middleton

n this report: Pacira Pharmaceuticals (NASDAQ:PCRX), Amtech Systems (NASDAQ:ASYS) and BioSante Pharmaceuticals (NASDAQ:BPAX).

Pacira Pharmaceuticals (NASDAQ:PCRX) has gained more than 11 percent today after the company announced a public offering of 7 million shares of its common stock of $6.50 …

Posted in Latest Headlines, Reports | Tagged Amtech Systems, analyst, ASYS, BioSante Pharmaceuticals, BPAX, common stock, company, expectations, forecast, LiBiGel, NASDAQ, NASDAQ:ASYS, NASDAQ:BPAX, NASDAQ:PCRX, net proceeds, offerings, Pacira Pharmaceuticals, PCRX, quarter, report, results, revenue, sale, shares, study, testosterone, traded, Wall Street | Comments Off

Mid-day Small Cap update (SAVW, EMIS, POSC)

Posted on November 14, 2011 by Josie Middleton

In this report: SavWatt USA (OTC:SAVW), Emisphere Technologies (OTC:EMIS) and Positron Corp. (OTC:POSC).

SavWatt USA (OTC:SAVW) is trading 10 percent higher today after the company announced that its Eco-Pole will be installed at the Fort Knox US Military Base. The …

Posted in Latest Headlines, Reports | Tagged Andy Will, company, Eco-Pole, EMIS, Emisphere Technologies, Fort Knox, letter of intent, Manhattan Isotope Technology, Novartis Pharma, OTC, OTC:EMIS, OTC:POSC, OTC:SAVW, Phase 3, POSC, Positron Corp., results, SAVW, SavWatt USA, small cap, study, trading, treatment | Comments Off

What’s up Medivation, MercadoLibre and Aeropostale?

Posted on November 3, 2011 by Martin Timble

In this report: Medivation Inc. (NASDAQ:MDVN), MercadoLibre Inc. (NASDAQ:MELI) and Aeropostale Inc. (NYSE:ARO).

Medivation Inc. (NASDAQ:MDVN) has soared by more than 116 percent today after the company reported results from a Phase 3 clinical trial study of its drug candidate …

Posted in Latest Headlines, Reports | Tagged Aeropostale Inc., analyst, ARO, candidate, clinical trial, company, drug, earnings, expectations, file, guidance, MDVN, Medivation Inc., MELI, MercadoLibre Inc., MV3100, NASDAQ, NASDAQ:MDVN, NASDAQ:MELI, NYSE, NYSE:ARO, outlook, patients, Phase 3, profits, prostate cancer, quarter, reported, resgulators, results, revenue, stores, study, trades, wall streets | Comments Off

What the fuss Leap Wireless, Exelixis and Amedisys?

Posted on November 1, 2011 by Martin Timble

In this report: Leap Wireless (NASDAQ:LEAP), Exelixis Inc. (NASDAQ:EXEL) and Amedisys Inc. (NASDAQ:AMED).

Leap Wireless (NASDAQ:LEAP) has gained more than 14.6 percent during trading so far today after the company reported an unexpected gain in subscribers in its third quarter. …

Posted in Latest Headlines, Reports | Tagged agreement, AMED, Amedisys Inc., cancer, company, COO, drug study, earnings, EXEL, Exelixis Inc., expectations, FDA, Food and Drug Administration, LEAP, Leap Wireless, NASDAQ, NASDAQ:AMED, NASDAQ:EXEL, NASDAQ:LEAP, net loss, outlook, patients, profits, prostate cancer, quarter, report, reported, revenue, share, study, subscribers, trading | Comments Off

What the Fuss HSX Health Soultions, Semgroup and Exelixis?

Posted on October 24, 2011 by Cameron White

In this report: HSX Health Solutions. (NASDAQ:SXCI), Semgroup Corp. (NYSE:SEMG) and Exelixis Inc. (NASDAQ:EXEL).

HSX Health Solutions. (NASDAQ:SXCI) is trading over 17 percent lower today after it was reported that Cigna (NYSE:CI) will acquire the Healthspring for $3.8 billion as …

Posted in Main Post, Reports | Tagged acquire, analyst, biotech, cabozantinib, CI, Cigna Solutions, Credit Suisse, drug, EXEL, Exelixis Inc., funded, hostile, HSX Health Solutions., launched, NASDAQ, NASDAQ:EXEL, NASDAQ:SXCI, NYSE, NYSE:SEMG, offer, Phase 3, Planis All American Pipeline, premium, reported, revenues, SEMG, Semgroup Corp., study, SXCI, takeover, trades, trading, treatment | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.